PARIS, July 01, 2021–(BUSINESS WIRE)–TISSIUM, a privately-owned medtech firm creating biomorphic programmable polymers for tissue reconstruction, introduced as we speak Romain Attard has been appointed Chief Monetary Officer of TISSIUM.
This press launch options multimedia. View the complete launch right here: https://www.businesswire.com/news/home/20210701005319/en/
TISSIUM Appoints Romain Attard as Chief Monetary Officer (Picture: TISSIUM)
Mr. Attard joins TISSIUM with an in depth background in company finance and Fairness Capital Markets having supported various mid-cap financing occasions in Europe and within the U.S, in addition to originating and executing mergers and acquisitions amongst private and non-private firms.
The addition of Mr. Attard to TISSIUM’s management crew is the most recent in a collection of govt appointments that embody Chief Enterprise Officer, Vice President of World Regulatory and Medical Affairs, and Vice President of World Operations. With a full govt suite overlaying its operations throughout Europe and the U.S., TISSIUM is staffed to help the enlargement it anticipates throughout the subsequent few years and to scale operations as wanted whereas constructing out its deliberate platform of merchandise.
Christophe Bancel, CEO of TISSIUM, stated: “We’re happy to welcome Romain to TISSIUM as we proceed to advance and develop the corporate. His huge expertise and deep monetary data will help our enlargement at this vital time, finally serving to to advance the TISSIUM platform as we stay centered on our aim of remodeling tissue reconstruction. Romain is a superb addition to an already sturdy worldwide management crew.”
Mr. Attard joins TISSIUM from ODDO BHF the place he spent a decade working in company finance. Most not too long ago, he served as Managing Director and Head of Public M&A and ECM. Notably, he supported quite a few IPOs in addition to capital will increase, delistings, takeovers, and others.
Mr. Attard stated: “I’m excited to affix TISSIUM to speed up the construct out of TISSIUM’s already spectacular platform. TISSIUM is getting into into a major interval of progress, and I stay up for enjoying a key function within the execution and additional improvement of the corporate’s monetary technique as we transfer into the corporate’s subsequent stage.”
TISSIUM is a privately-owned medtech firm primarily based in Paris, France that’s devoted to the fast improvement and commercialization of a novel biopolymer platform to deal with numerous unmet medical wants.
The corporate’s platform is predicated on a proprietary polymer household with distinctive properties together with the flexibility to adapt to and combine with surrounding tissue to allow tissue reconstruction. Moreover, the polymer constructing blocks allow customization to match tissue-specific necessities for various therapeutic areas. The corporate is creating a portfolio of options for peripheral nerve, gastrointestinal, ENT and cardiovascular purposes. The corporate additionally develops supply and activation units for enhanced efficiency and value of its household of polymers.
TISSIUM’s expertise is predicated on world-class analysis and mental property from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Girls’s Hospital), who co-founded the corporate in 2013. For extra info, please go to: www.TISSIUM.com and @TISSIUMtech.
View supply model on businesswire.com: https://www.businesswire.com/news/home/20210701005319/en/
Brice Epry – Chief of Workers
Tel: +33 1 76 21 72 28
Tel: +1 646-770-8858